Next Article in Journal
Advances in Multiple Sclerosis 2017
Next Article in Special Issue
Cell-Specific PEAR1 Methylation Studies Reveal a Locus that Coordinates Expression of Multiple Genes
Previous Article in Journal
Individual versus Combinatorial Effects of Silicon, Phosphate, and Iron Deficiency on the Growth of Lowland and Upland Rice Varieties
Previous Article in Special Issue
DNA Methylation Levels of the ELMO Gene Promoter CpG Islands in Human Glioblastomas
Open AccessArticle

Evaluation of Promoter Methylation of RASSF1A and ATM in Peripheral Blood of Breast Cancer Patients and Healthy Control Individuals

1
Molecular Biology of Breast Cancer, Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg 69120, Germany
2
Division of Molecular Epidemiology (C080), German Cancer Research Center (DKFZ), Heidelberg 69120, Germany
3
Division of Biostatistics (C060), German Cancer Research Center (DKFZ), Heidelberg 69120, Germany
4
Department of Gynecology and Obstetrics, University Women’s Clinic, Heidelberg 69120, Germany
5
National Centre for Tumor Diseases, Heidelberg 69120, Germany
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(3), 900; https://doi.org/10.3390/ijms19030900
Received: 2 March 2018 / Revised: 11 March 2018 / Accepted: 12 March 2018 / Published: 19 March 2018
(This article belongs to the Special Issue DNA Methylation)
Breast cancer (BC) is the most common cancer among women and has high mortality rates. Early detection is supposed to be critical for the patient’s prognosis. In recent years, several studies have investigated global DNA methylation profiles and gene-specific DNA methylation in blood-based DNA to develop putative screening markers for cancer. However, most of the studies have not yet been validated. In our study, we analyzed the promoter methylation of RASSF1A and ATM in peripheral blood DNA of 229 sporadic patients and 151 healthy controls by the MassARRAY EpiTYPER assay. There were no significant differences in DNA methylation levels of RASSF1A and ATM between the sporadic BC cases and the healthy controls. Furthermore, we performed the Infinium HumanMethylation450 BeadChip (450K) array analysis using 48 sporadic BC cases and 48 healthy controls (cases and controls are the same from those of the MassARRAY EpiTYPER assay) and made a comparison with the published data. No significant differences were presented in DNA methylation levels of RASSF1A and ATM between the sporadic BC cases and the healthy controls. So far, the evidence for powerful blood-based methylation markers is still limited and the identified markers need to be further validated. View Full-Text
Keywords: breast cancer; DNA methylation; RASSF1A; ATM breast cancer; DNA methylation; RASSF1A; ATM
MDPI and ACS Style

Cao, X.; Tang, Q.; Holland-Letz, T.; Gündert, M.; Cuk, K.; Schott, S.; Heil, J.; Golatta, M.; Sohn, C.; Schneeweiss, A.; Burwinkel, B. Evaluation of Promoter Methylation of RASSF1A and ATM in Peripheral Blood of Breast Cancer Patients and Healthy Control Individuals. Int. J. Mol. Sci. 2018, 19, 900.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop